GPCR Activation of Ras and PI3KΓ in Neutrophils
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Supplemental Information
Supplemental information Dissection of the genomic structure of the miR-183/96/182 gene. Previously, we showed that the miR-183/96/182 cluster is an intergenic miRNA cluster, located in a ~60-kb interval between the genes encoding nuclear respiratory factor-1 (Nrf1) and ubiquitin-conjugating enzyme E2H (Ube2h) on mouse chr6qA3.3 (1). To start to uncover the genomic structure of the miR- 183/96/182 gene, we first studied genomic features around miR-183/96/182 in the UCSC genome browser (http://genome.UCSC.edu/), and identified two CpG islands 3.4-6.5 kb 5’ of pre-miR-183, the most 5’ miRNA of the cluster (Fig. 1A; Fig. S1 and Seq. S1). A cDNA clone, AK044220, located at 3.2-4.6 kb 5’ to pre-miR-183, encompasses the second CpG island (Fig. 1A; Fig. S1). We hypothesized that this cDNA clone was derived from 5’ exon(s) of the primary transcript of the miR-183/96/182 gene, as CpG islands are often associated with promoters (2). Supporting this hypothesis, multiple expressed sequences detected by gene-trap clones, including clone D016D06 (3, 4), were co-localized with the cDNA clone AK044220 (Fig. 1A; Fig. S1). Clone D016D06, deposited by the German GeneTrap Consortium (GGTC) (http://tikus.gsf.de) (3, 4), was derived from insertion of a retroviral construct, rFlpROSAβgeo in 129S2 ES cells (Fig. 1A and C). The rFlpROSAβgeo construct carries a promoterless reporter gene, the β−geo cassette - an in-frame fusion of the β-galactosidase and neomycin resistance (Neor) gene (5), with a splicing acceptor (SA) immediately upstream, and a polyA signal downstream of the β−geo cassette (Fig. -
Supplementary Table S2
1-high in cerebrotropic Gene P-value patients Definition BCHE 2.00E-04 1 Butyrylcholinesterase PLCB2 2.00E-04 -1 Phospholipase C, beta 2 SF3B1 2.00E-04 -1 Splicing factor 3b, subunit 1 BCHE 0.00022 1 Butyrylcholinesterase ZNF721 0.00028 -1 Zinc finger protein 721 GNAI1 0.00044 1 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 GNAI1 0.00049 1 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 PDE1B 0.00069 -1 Phosphodiesterase 1B, calmodulin-dependent MCOLN2 0.00085 -1 Mucolipin 2 PGCP 0.00116 1 Plasma glutamate carboxypeptidase TMX4 0.00116 1 Thioredoxin-related transmembrane protein 4 C10orf11 0.00142 1 Chromosome 10 open reading frame 11 TRIM14 0.00156 -1 Tripartite motif-containing 14 APOBEC3D 0.00173 -1 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D ANXA6 0.00185 -1 Annexin A6 NOS3 0.00209 -1 Nitric oxide synthase 3 SELI 0.00209 -1 Selenoprotein I NYNRIN 0.0023 -1 NYN domain and retroviral integrase containing ANKFY1 0.00253 -1 Ankyrin repeat and FYVE domain containing 1 APOBEC3F 0.00278 -1 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F EBI2 0.00278 -1 Epstein-Barr virus induced gene 2 ETHE1 0.00278 1 Ethylmalonic encephalopathy 1 PDE7A 0.00278 -1 Phosphodiesterase 7A HLA-DOA 0.00305 -1 Major histocompatibility complex, class II, DO alpha SOX13 0.00305 1 SRY (sex determining region Y)-box 13 ABHD2 3.34E-03 1 Abhydrolase domain containing 2 MOCS2 0.00334 1 Molybdenum cofactor synthesis 2 TTLL6 0.00365 -1 Tubulin tyrosine ligase-like family, member 6 SHANK3 0.00394 -1 SH3 and multiple ankyrin repeat domains 3 ADCY4 0.004 -1 Adenylate cyclase 4 CD3D 0.004 -1 CD3d molecule, delta (CD3-TCR complex) (CD3D), transcript variant 1, mRNA. -
Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A. -
Supplementary Table S1. List of Mirnas on Human Chromosome 3P and the Changes of Their Genome Copies Determined by Genomic Real-Time PCR
Supplementary Table S1. List of miRNAs on human chromosome 3p and the changes of their genome copies determined by genomic real-time PCR. Change of frequency, ID Accession Chromosome Start End Strand genome copy % hsa-mir-378b MI0014154 3p25.3 10371913 10371969 + No difference hsa-mir-885 MI0005560 3p25.3 10436173 10436246 - Deletion 25% hsa-mir-4270 MI0015878 3p25.1 15537746 15537815 - Amplification 80% hsa-mir-3134 MI0014155 3p25.1 15738805 15738878 - No difference hsa-mir-563 MI0003569 3p25.1 15915278 15915356 + No difference hsa-mir-3714 MI0016135 3p24.3 16974688 16974752 + No difference hsa-mir-4791 MI0017438 3p24.3 19356340 19356423 - No difference hsa-mir-3135a MI0014156 3p24.3 20179057 20179133 + No difference hsa-mir-4792 MI0017439 3p24.2 24562853 24562926 - Deletion 35% hsa-mir-4442 MI0016785 3p24.2 25706364 25706430 - No difference hsa-mir-466 MI0014157 3p23 31203196 31203279 - No difference hsa-mir-128-2 MI0000727 3p22.3 35785968 35786051 + Deletion 75% hsa-mir-26a-1 MI0000083 3p22.2 38010895 38010971 + Deletion 35% hsa-mir-138-1 MI0000476 3p21.32 44155704 44155802 + Deletion 25% hsa-mir-564 MI0003570 3p21.31 44903380 44903473 + Deletion 25% hsa-mir-1226 MI0006313 3p21.31 47891045 47891119 + No difference hsa-mir-4443 MI0016786 3p21.31 48238054 48238106 + No difference hsa-mir-2115 MI0010634 3p21.31 48357850 48357949 - No difference hsa-mir-711 MI0012488 3p21.31 48616335 48616410 - No difference hsa-mir-4793 MI0017440 3p21.31 48681627 48681713 - No difference hsa-mir-425 MI0001448 3p21.31 49057581 49057667 - Amplification 65% -
Clinical Impact of Copy Number Variation Changes in Bladder Cancer Samples
EXPERIMENTAL AND THERAPEUTIC MEDICINE 22: 901, 2021 Clinical impact of copy number variation changes in bladder cancer samples VICTORIA SPASOVA1, BORIS MLADENOV2, SIMEON RANGELOV3, ZORA HAMMOUDEH1, DESISLAVA NESHEVA1, DIMITAR SERBEZOV1, RADA STANEVA1,4, SAVINA HADJIDEKOVA1,4, MIHAIL GANEV1, LUBOMIR BALABANSKI1,5, RADOSLAVA VAZHAROVA5,6, CHAVDAR SLAVOV3, DRAGA TONCHEVA1 and OLGA ANTONOVA1 1Department of Medical Genetics, Medical University‑Sofia, 1431 Sofia;2 Department of Urology, UMBALSM N.I. Pirogov, 1606 Sofia; 3Department of Urology, Tsaritsa Yoanna University Hospital, 1527 Sofia; 4Medical Genetics Laboratory, Nadezhda Women's Health Hospital, 1373 Sofia; 5Medical Genetics Laboratory, GARH Malinov, 1680 Sofia; 6Department of Biology, Medical Genetics and Microbiology, Faculty of Medicine, Sofia University St. Kliment Ohridski, 1407 Sofia, Bulgaria Received November 30, 2019; Accepted February 18, 2021 DOI: 10.3892/etm.2021.10333 Abstract. The aim of the present study was to detect copy uroepithelial tumours may lay a foundation for implementing number variations (CNVs) related to tumour progression and molecular CNV profiling of bladder tumours as part of a metastasis of urothelial carcinoma through whole‑genome routine progression risk estimation strategy, thus expanding scanning. A total of 30 bladder cancer samples staged from the personalized therapeutic approach. pTa to pT4 were included in the study. DNA was extracted from freshly frozen tissue via standard phenol‑chloroform extraction Introduction and CNV analysis was performed on two alternative platforms (CytoChip Oligo aCGH, 4x44K and Infinium OncoArray‑500K The most successful approach to treating a disease has BeadChip; Illumina, Inc.). Data were analysed with BlueFuse always been etiological therapy. In the case of bladder Multi software and Karyostudio, respectively. -
Supplementary Table 1
Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7 -
Effect of Low Doses of Estradiol and Tamoxifen on Breast Cancer Cell Karyotypes
238 M Rondón-Lagos et al. Breast cancer cell karyotypes, 23:8 635–650 Research E2 and tamoxifen Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes Milena Rondón-Lagos1, Nelson Rangel1,2, Ludovica Verdun Di Cantogno3, Laura Annaratone1, Isabella Castellano1, Rosalia Russo1, Tilde Manetta4, Caterina Marchiò1,* and Anna Sapino1,5,* 1Department of Medical Sciences, University of Turin, Turin, Italy Correspondence 2Natural and Mathematical Sciences Faculty, Universidad del Rosario, Bogotá, Colombia should be addressed 3Pathology Division, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy to C Marchiò or A Sapino 4Department of Public Health and Pediatrics, University of Turin, Turin, Italy Email 5Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy [email protected] or *(C Marchiò and A Sapino contributed equally to this work) [email protected] Abstract Evidence supports a role of 17β-estradiol (E2) in carcinogenesis and the large majority Key Words of breast carcinomas are dependent on estrogen. The anti-estrogen tamoxifen (TAM) f breast cancer cells is widely used for both treatment and prevention of breast cancer; however, it is also f estradiol carcinogenic in human uterus and rat liver, highlighting the profound complexity of its f tamoxifen actions. The nature of E2- or TAM-induced chromosomal damage has been explored using f chromosomal relatively high concentrations of these agents, and only some numerical aberrations abnormalities Endocrine-Related Cancer Endocrine-Related and chromosomal breaks have been analyzed. This study aimed to determine the effects f chromosomal instability −8 −1 −6 −1 of low doses of E2 and TAM (10 mol L and 10 mol L respectively) on karyotypes of MCF7, T47D, BT474, and SKBR3 breast cancer cells by comparing the results of conventional karyotyping and multi-FISH painting with cell proliferation. -
Primepcr™Assay Validation Report
PrimePCR™Assay Validation Report Gene Information Gene Name breast cancer anti-estrogen resistance protein 3 Gene Symbol Bcar3 Organism Rat Gene Summary Description Not Available Gene Aliases Not Available RefSeq Accession No. Not Available UniGene ID Rn.7383 Ensembl Gene ID ENSRNOG00000013737 Entrez Gene ID 310838 Assay Information Unique Assay ID qRnoCIP0035724 Assay Type Probe - Validation information is for the primer pair using SYBR® Green detection Detected Coding Transcript(s) ENSRNOT00000065111 Amplicon Context Sequence GCAAGGTTGCTAGGATACTGGAAGTCTCTGAAGACATGAAGAGGAGCATGGGC GTGAGCTCGGGACTGGAACTCATTACCTTGCCTCACGGACGCCAGCTGCGCCT GGACATTATTGAAAGACACAACACCATGGCCATTG Amplicon Length (bp) 111 Chromosome Location 2:246024723-246034495 Assay Design Intron-spanning Purification Desalted Validation Results Efficiency (%) 103 R2 0.9986 cDNA Cq 21.98 cDNA Tm (Celsius) 85.5 gDNA Cq 37.5 Specificity (%) 100 Information to assist with data interpretation is provided at the end of this report. Page 1/4 PrimePCR™Assay Validation Report Bcar3, Rat Amplification Plot Amplification of cDNA generated from 25 ng of universal reference RNA Melt Peak Melt curve analysis of above amplification Standard Curve Standard curve generated using 20 million copies of template diluted 10-fold to 20 copies Page 2/4 PrimePCR™Assay Validation Report Products used to generate validation data Real-Time PCR Instrument CFX384 Real-Time PCR Detection System Reverse Transcription Reagent iScript™ Advanced cDNA Synthesis Kit for RT-qPCR Real-Time PCR Supermix SsoAdvanced™ SYBR® Green Supermix Experimental Sample qPCR Reference Total RNA Data Interpretation Unique Assay ID This is a unique identifier that can be used to identify the assay in the literature and online. Detected Coding Transcript(s) This is a list of the Ensembl transcript ID(s) that this assay will detect. -
Protein Annotation of Breast-Cancer-Related Proteins with Machine-Learning Tools
Makara Journal of Science Volume 24 Issue 2 June Article 6 6-26-2020 Protein Annotation of Breast-cancer-related Proteins with Machine-learning Tools Arli Aditya Parikesit Department of Bioinformatics, School of Life Sciences, Indonesia International Institute for Life Sciences, Jakarta 13210, Indonesia, [email protected] David Agustriawan Department of Bioinformatics, School of Life Sciences, Indonesia International Institute for Life Sciences, Jakarta 13210, Indonesia Rizky Nurdiansyah Department of Bioinformatics, School of Life Sciences, Indonesia International Institute for Life Sciences, Jakarta 13210, Indonesia Follow this and additional works at: https://scholarhub.ui.ac.id/science Recommended Citation Parikesit, Arli Aditya; Agustriawan, David; and Nurdiansyah, Rizky (2020) "Protein Annotation of Breast- cancer-related Proteins with Machine-learning Tools," Makara Journal of Science: Vol. 24 : Iss. 2 , Article 6. DOI: 10.7454/mss.v24i1.12106 Available at: https://scholarhub.ui.ac.id/science/vol24/iss2/6 This Article is brought to you for free and open access by the Universitas Indonesia at UI Scholars Hub. It has been accepted for inclusion in Makara Journal of Science by an authorized editor of UI Scholars Hub. Protein Annotation of Breast-cancer-related Proteins with Machine-learning Tools Cover Page Footnote The authors would like to thank the Institute for Research and Community Services of the Indonesia International Institute for Life Sciences (i3l) for their heartfelt support. Thanks also goes to Direktorat Riset dan Pengabdian Masyarakat, Direktorat Jenderal Penguatan Riset dan Pengembangan Kementerian Riset, Teknologi dan Pendidikan Tinggi Republik Indonesia for providing Hibah Penelitian Dasar DIKTI/ LLDIKTI III 2019 No. 1/AKM/PNT/2019. -
Breast Cancer Antiestrogen Resistance-3 (BCAR3) in Mammary Gland Development and Breast Cancer
Breast Cancer Antiestrogen Resistance-3 (BCAR3) in mammary gland development and breast cancer Allison Margarethe Cross Royersford, PA B.S. Lycoming College 2010 A Dissertation presented to the Graduate Faculty of the University of Virginia in Candidacy for the Degree of Doctor of Philosophy Department of Microbiology, Immunology, and Cancer University of Virginia May, 2016 i Abstract Despite increased early detection and improved treatment options, breast cancer remains the second leading cause of cancer deaths among women. The majority of breast cancer mortalities are the consequence of therapeutic-resistant metastatic disease. A better understanding of the genetic alterations and signaling pathways involved in breast cancer progression and therapeutic resistance is required to identify new and better therapeutic targets to combat this disease. Breast Cancer Antiestrogen-3 (BCAR3) has been identified as an adaptor molecule that is upregulated in aggressive breast cancer cell lines, where it contributes to increased proliferation, migration, and invasion. The work presented in this thesis focuses on understanding BCAR3 signaling in breast cancer progression as well as mammary gland morphogenesis. The data presented demonstrate that BCAR3 controls adhesion turnover, migration, and invasion through interactions with the adaptor molecule p130Cas (Cas). In addition, BCAR3 was found to be upregulated and differentially expressed during tumor progression in the MMTV-polyoma middle T (PyMT) mouse model of spontaneous breast cancer. Preliminary xenograft studies in mice reveal that BCAR3 expression accelerates tumor formation and controls total tumor burden in MDA-MB-231 breast tumors. Future studies are needed to determine if BCAR3 can regulate the growth of established tumors and promote metastasis, and if interactions with Cas are required for its functions in vivo. -
Rabbit Anti-Phospho-BCAR1-SL12575R
SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-phospho-BCAR1 SL12575R-FITC Product Name: Anti-phospho-BCAR1 (Tyr751)/FITC Chinese Name: FITC标记的磷酸化乳腺癌抗雌激素耐药蛋白1抗体 BCAR1 (phospho Y751); BCAR1(phospho Y751); p-BCAR1(p-Tyr751); Breast cancer anti estrogen resistance 1 protein; BCAR 1; Bcar1; BCAR1_HUMAN; Breast cancer Alias: anti estrogen resistance 1; Breast cancer anti-estrogen resistance protein 1; CAS; Cas scaffolding protein family member 1; Crk associated substrate; Crk associated substrate p130Cas; CRK-associated substrate; CRKAS; P130CAS. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat, ICC=1:50-200IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 93kDa Cellular localization: The cell membrane Form: Lyophilized or Liquid Concentration: 1mg/mlwww.sunlongbiotech.com KLH conjugated synthesised phosphopeptide derived from human BCAR1 around the immunogen: phosphorylation site of Tyr751 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. background: Product Detail: p130 represents one of several known substrates for v-Crk encoded p47. p130 Cas (for Crk-associated substrate) exhibits a high level of tyrosine phosphorylation and is tightly associated with v-Crk, suggesting a role in v-Crk-mediated cell signaling. -
Downregulation of Carnitine Acyl-Carnitine Translocase by Mirnas
Page 1 of 288 Diabetes 1 Downregulation of Carnitine acyl-carnitine translocase by miRNAs 132 and 212 amplifies glucose-stimulated insulin secretion Mufaddal S. Soni1, Mary E. Rabaglia1, Sushant Bhatnagar1, Jin Shang2, Olga Ilkayeva3, Randall Mynatt4, Yun-Ping Zhou2, Eric E. Schadt6, Nancy A.Thornberry2, Deborah M. Muoio5, Mark P. Keller1 and Alan D. Attie1 From the 1Department of Biochemistry, University of Wisconsin, Madison, Wisconsin; 2Department of Metabolic Disorders-Diabetes, Merck Research Laboratories, Rahway, New Jersey; 3Sarah W. Stedman Nutrition and Metabolism Center, Duke Institute of Molecular Physiology, 5Departments of Medicine and Pharmacology and Cancer Biology, Durham, North Carolina. 4Pennington Biomedical Research Center, Louisiana State University system, Baton Rouge, Louisiana; 6Institute for Genomics and Multiscale Biology, Mount Sinai School of Medicine, New York, New York. Corresponding author Alan D. Attie, 543A Biochemistry Addition, 433 Babcock Drive, Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, (608) 262-1372 (Ph), (608) 263-9608 (fax), [email protected]. Running Title: Fatty acyl-carnitines enhance insulin secretion Abstract word count: 163 Main text Word count: 3960 Number of tables: 0 Number of figures: 5 Diabetes Publish Ahead of Print, published online June 26, 2014 Diabetes Page 2 of 288 2 ABSTRACT We previously demonstrated that micro-RNAs 132 and 212 are differentially upregulated in response to obesity in two mouse strains that differ in their susceptibility to obesity-induced diabetes. Here we show the overexpression of micro-RNAs 132 and 212 enhances insulin secretion (IS) in response to glucose and other secretagogues including non-fuel stimuli. We determined that carnitine acyl-carnitine translocase (CACT, Slc25a20) is a direct target of these miRNAs.